Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 9/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.51 |
| ▸ | CASP1 | P29466 | 8/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | CASP4 | P49662 | 1/20 | 0.48 |
| ▸ | CASP5 | P51878 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917395 | 0.83 | CAPN1 (0.52) | CAPN1HPGD | |
| SCHEMBL8676349 | 0.83 | CAPN1 (0.52) | CAPN1HPGD | |
| SCHEMBL8676342 | 0.83 | CAPN1 (0.52) | CAPN1HPGD | |
| SCHEMBL280633 | 0.83 | ALDH1A1 (0.55) | CAPN1HPGD | |
| SCHEMBL13570313 | 0.83 | CTRB1 (0.55) | CAPN1HPGD | |
| SCHEMBL7378642 | 0.81 | CAPN1 (0.74) | CAPN1HPGD | |
| SCHEMBL40781 | 0.81 | CAPN1 (0.74) | CAPN1HPGD | |
| SCHEMBL13951156 | 0.80 | CASP1 (0.52) | CASP3CASP1CASP8 | |
| SCHEMBL13928412 | 0.80 | CASP1 (0.52) | CASP3CASP1CASP8 | |
| SCHEMBL13018398 | 0.80 | CASP1 (0.52) | CASP3CASP1CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481722-B1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2014-08-27 | — | — | EP | disclosed |
| US-8471057-B2 | Sitagliptin intermediates, preparation methods and uses thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2013-06-25 | — | — | US | disclosed |
| EP-2481722-A1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2012-08-01 | — | — | EP | disclosed |
| US-20120178957-A1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178957-A1 | SITAGLIPTIN INTERMEDIATES, PREPARATION METHODS AND USES THEREOF | DPP4, DPP8, DPP9 | CASP3 781/4885CAPN1 3439/4885CASP1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.